Erik A. Nelson

3.1k citations

38 papers · 2.3k indexed · 1 hit paper · h-index 23

Molecular Biology top 10%
Oncology top 5%
Immunology top 5%
Hematology top 2%
Genetics top 5%

Co-authors: David A. Frank Sarah R. Walker Fabrice Porcheray Mehrdad Mohseni Christine Canning Robert J. Soiffer Emmanuel Zorn Roberto Bellucci
Topics: Cytokine Signaling Pathways and Interactions (13 papers)Chronic Myeloid Leukemia Treatments (11 papers)Acute Myeloid Leukemia Research (10 papers)
Cited by: Hematology Immunology Oncology
Journals: Journal of Biological Chemistry Blood PLoS ONE
Partner nations: United States China Switzerland

In The Last Decade

Erik A. Nelson

38 papers receiving 2.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

IL-2 regulates FOXP3 expression in human CD4+CD25+ regulatory T cells through a STAT-dependent mechanism and induces the expansion of these cells in vivo

2006 601 citations Erik A. Nelson, David A. Frank et al. profile →

Peers

Countries citing papers authored by Erik A. Nelson

Since Specialization

Citations

This map shows the geographic impact of Erik A. Nelson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Erik A. Nelson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Erik A. Nelson more than expected).

Fields of papers citing papers by Erik A. Nelson

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Erik A. Nelson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Erik A. Nelson. The network helps show where Erik A. Nelson may publish in the future.

Co-authorship network of co-authors of Erik A. Nelson

This figure shows the co-authorship network connecting the top 25 collaborators of Erik A. Nelson. A scholar is included among the top collaborators of Erik A. Nelson based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Erik A. Nelson. Erik A. Nelson is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	CDK5RAP3 is a co-factor for the oncogenic transcription factor STAT3 2019 ·Neoplasia ·Susana P. Egusquiaguirre,Suhu Liu,(unknown),(unknown),Sarah R. Walker,(unknown),Tzuen Yih Saw,Michael Xiang,(unknown),Erik A. Nelson,David A. Frank	14
2	Upregulation of IGF1R by Mutant RAS in Leukemia and Potentiation of RAS Signaling Inhibitors by Small-Molecule Inhibition of IGF1R 2014 ·Clinical Cancer Research ·Ellen Weisberg,Atsushi Nonami,Chen Zhao,Erik A. Nelson,Yongfei Chen,(unknown),(unknown),Jianming Zhang,Martin Sattler,Constantine S. Mitsiades,Kwok‐Kin Wong,Qingsong Liu,Nathanael S. Gray,James D. Griffin	14
3	Targeting STAT5 in Hematologic Malignancies through Inhibition of the Bromodomain and Extra-Terminal (BET) Bromodomain Protein BRD2 2014 ·Molecular Cancer Therapeutics ·Suhu Liu,Sarah R. Walker,Erik A. Nelson,(unknown),Michael Xiang,Patricia A. Toniolo,Jun Qi,Richard M. Stone,Martha Wadleigh,James E. Bradner,David A. Frank	51
4	Identification of Wee1 as a novel therapeutic target for mutant RAS-driven acute leukemia and other malignancies 2014 ·Leukemia ·Ellen Weisberg,Atsushi Nonami,(unknown),F. Liu,Jianming Zhang,Martin Sattler,Erik A. Nelson,Kristen Cowens,Amanda L. Christie,C Mitsiades,Kwok‐Kin Wong,Qingyun Liu,Nathanael S. Gray,J D Griffin	49
5	Crucial role of Plexin C1 for pulmonary inflammation and survival during lung injury 2013 ·Mucosal Immunology ·Tiago Granja,D. Köhler,Valbona Mirakaj,Erik A. Nelson,Klemens König,Peter Rosenberger	22
6	STAT5 Outcompetes STAT3 To Regulate the Expression of the Oncogenic Transcriptional Modulator BCL6 2013 ·Molecular and Cellular Biology ·Sarah R. Walker,Erik A. Nelson,Jennifer Yeh,Luca Pinello,Guo‐Cheng Yuan,David A. Frank	69
7	Selective Akt Inhibitors Synergize with Tyrosine Kinase Inhibitors and Effectively Override Stroma-Associated Cytoprotection of Mutant FLT3-Positive AML Cells 2013 ·PLoS ONE ·Ellen Weisberg,Qingsong Liu,Xin Zhang,Erik A. Nelson,Martin Sattler,Feiyang Liu,(unknown),Jianming Zhang,Constantine S. Mitsiades,Robert W. Smith,Richard M. Stone,Ilene Galinsky,Atsushi Nonami,James D. Griffin,Nathanael S. Gray	37
8	STAT signaling in the pathogenesis and treatment of myeloid malignancies 2012 ·PubMed ·Michal Bar‐Natan,Erik A. Nelson,Michael Xiang,David A. Frank	70
9	An amino-indazole scaffold with spectrum selective kinase inhibition of FLT3, PDGFRα and kit 2012 ·Bioorganic & Medicinal Chemistry Letters ·Xianming Deng,Wenjun Zhou,Ellen Weisberg,Jinhua Wang,Jianming Zhang,Takaaki Sasaki,Erik A. Nelson,James D. Griffin,Pasi A. Jänne,Nathanael S. Gray	12
10	Using combination therapy to override stromal-mediated chemoresistance in mutant FLT3-positive AML: synergism between FLT3 inhibitors, dasatinib/multi-targeted inhibitors and JAK inhibitors 2012 ·Leukemia ·Ellen Weisberg,Qingsong Liu,Erik A. Nelson,Andrew L. Kung,Amanda L. Christie,Rod T. Bronson,Martin Sattler,Takaomi Sanda,Zheng Zhao,Won Hur,C Mitsiades,(unknown),J F Daley,Richard M. Stone,Ilene Galinsky,J D Griffin,Nathanael S. Gray	61
11	Reversible Resistance Induced by FLT3 Inhibition: A Novel Resistance Mechanism in Mutant FLT3-Expressing Cells 2011 ·PLoS ONE ·Ellen Weisberg,Arghya Ray,Erik A. Nelson,Sophia Adamia,Rosemary Barrett,Martin Sattler,Chengsheng Zhang,John Daley,David A. Frank,Edward Fox,James D. Griffin	38
12	Pyrimethamine inhibits adult polycystic kidney disease by modulating STAT signaling pathways 2011 ·Human Molecular Genetics ·Ayumi Takakura,Erik A. Nelson,(unknown),Benjamin D. Humphreys,Kambiz Zandi‐Nejad,David A. Frank,Jing Zhou	107
13	A Chemical Biology Approach to Developing STAT Inhibitors: Molecular Strategies for Accelerating Clinical Translation 2011 ·Oncotarget ·Erik A. Nelson,Sreenath V. Sharma,Jeffrey Settleman,David A. Frank	71
14	Discovery and Characterization of Novel Mutant FLT3 Kinase Inhibitors 2010 ·Molecular Cancer Therapeutics ·Ellen Weisberg,Hwan Geun Choi,Rosemary Barrett,Wenjun Zhou,Jianming Zhang,Arghya Ray,Erik A. Nelson,Jingrui Jiang,Daisy Moreno,Richard M. Stone,Ilene Galinsky,Edward Fox,Sophia Adamia,Andrew L. Kung,Nathanael S. Gray,James D. Griffin	12
15	Microtubule-Targeted Chemotherapeutic Agents Inhibit Signal Transducer and Activator of Transcription 3 (STAT3) Signaling 2010 ·Molecular Pharmacology ·Sarah R. Walker,(unknown),Erik A. Nelson,David A. Frank	54
16	Smac mimetics: implications for enhancement of targeted therapies in leukemia 2010 ·Leukemia ·Ellen Weisberg,Arghya Ray,Rosemary Barrett,Erik A. Nelson,Amanda L. Christie,Dale Porter,(unknown),Leigh Zawel,John Daley,(unknown),Richard Stone,(unknown),David A. Frank,Andrew L. Kung,James D. Griffin	76
17	Reciprocal Effects of STAT5 and STAT3 in Breast Cancer 2009 ·Molecular Cancer Research ·Sarah R. Walker,Erik A. Nelson,Lihua Zou,(unknown),Sabina Signoretti,Andrea L. Richardson,David A. Frank	107
18	STAT5 represses BCL6 expression by binding to a regulatory region frequently mutated in lymphomas 2006 ·Oncogene ·Sarah R. Walker,Erik A. Nelson,David A. Frank	91
19	Identification of Human STAT5-dependent Gene Regulatory Elements Based on Interspecies Homology 2006 ·Journal of Biological Chemistry ·Erik A. Nelson,Sarah R. Walker,(unknown),X. Shirley Liu,David A. Frank	22
20	Isolation of Unique STAT5 Targets by Chromatin Immunoprecipitation-based Gene Identification 2004 ·Journal of Biological Chemistry ·Erik A. Nelson,Sarah R. Walker,James V. Alvarez,David A. Frank	64

About Erik A. Nelson

Erik A. Nelson is a scholar working on Hematology, Genetics and Oncology, having authored 38 papers that have together received 2.3k indexed citations. Recurring topics across this work include Cytokine Signaling Pathways and Interactions (13 papers), Chronic Myeloid Leukemia Treatments (11 papers) and Acute Myeloid Leukemia Research (10 papers). The work is most often cited by research in Hematology (530 citations), Immunology (869 citations) and Oncology (887 citations). Erik A. Nelson has collaborated with scholars based in United States, China and Switzerland. Frequent co-authors include David A. Frank, Sarah R. Walker, Fabrice Porcheray, Mehrdad Mohseni, Christine Canning, Robert J. Soiffer, Emmanuel Zorn, Roberto Bellucci, Jerome Ritz and Elke Raderschall. Their work appears in journals such as Journal of Biological Chemistry, Blood and PLoS ONE.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact